Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | PRKDC | P78527 | 1/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16563872 | 0.89 | SLC6A4 (0.42) | SLC6A4SLC6A2SLC6A3PDE2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL16634012 | 0.87 | SLC6A4 (0.41) | SLC6A4SLC6A2SLC6A3PDE2AALDH1A1 | |
| SCHEMBL16563914 | 0.84 | SLC6A4 (0.39) | SLC6A4SLC6A2SLC6A3PRKDCPDE2A | |
| SCHEMBL16563814 | 0.78 | CTSS (0.40) | SLC6A4CTSSABL1KCNH2 | |
| SCHEMBL12789414 | 0.73 | IDO1 (0.41) | DPP4 | |
| SCHEMBL18291931 | 0.72 | PDE2A (0.41) | EPHX2SLC6A4SLC6A3PDE2AHRH3 | |
| SCHEMBL12473628 | 0.72 | KCNH2 (0.44) | EPHX2PRKDCHRH3ABL1KDM1A | |
| SCHEMBL16861435 | 0.72 | PDE2A (0.44) | EPHX2SLC6A4SLC6A2SLC6A3PDE2A | |
| SCHEMBL28577438 | 0.71 | CTSS (0.43) | CTSSKCNH2 | |
| SCHEMBL24017149 | 0.70 | PDE2A (0.49) | EPHX2SLC6A4SLC6A2SLC6A3PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017508-B2 | Nitrogenated heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-07-10 | — | — | US | disclosed |
| EP-2848618-B1 | NITROGENATED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-03-14 | — | — | EP | disclosed |
| US-20170129887-A1 | NITROGENATED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-05-11 | — | — | US | disclosed |
| US-9469637-B2 | Nitrogenated heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-18 | — | — | US | disclosed |
| US-20150105373-A1 | NITROGENATED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-16 | — | — | US | disclosed |
| EP-2848618-A1 | NITROGENATED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105373-A1 | NITROGENATED HETEROCYCLIC COMPOUND | PDE2A, PDE5A, PDE3A | EPHX2 1190/4885SLC6A4 338/4885SLC6A2 38/4885 |
| US-20170129887-A1 | NITROGENATED HETEROCYCLIC COMPOUND | PDE2A, PDE5A, PDE3A | EPHX2 1190/4885SLC6A4 338/4885SLC6A2 38/4885 |
| US-10017508-B2 | Nitrogenated heterocyclic compound | PDE2A, PDE5A, PDE3A | EPHX2 1190/4885SLC6A4 338/4885SLC6A2 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.